Prevalence of Phototherapy in the Age of Biologics

被引：6

作者：

Calzavara-Pinton, Piergiacomo ^{[1
]}

Zanca, Arianna ^{[1
]}

Arisi, Mariachiara ^{[1
]}

Rossi, Maria Teresa ^{[1
]}

Zane, Cristina ^{[1
]}

Venturini, Marina ^{[1
]}

Ortel, Bernhard ^{[2
]}

机构：

[1] Univ Brescia, ASST Spedali Civili Brescia, Dept Dermatol, Ple Spedali Civili 1, IT-25126 Brescia, Italy

[2] NorthShore Univ HealthSyst, Skokie, IL USA

来源：

DERMATOLOGY | 2018年 / 234卷 / 5-6期

关键词：

Psoriasis; Biologic drugs; Phototherapy; European Medicines Agency; PSORIASIS; SURVIVAL; REGISTRY;

D O I：

10.1159/000491782

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment. Objectives: To quantify the use of phototherapy, biologics or conventional treatments in psoriasis, in a setting where European Medicines Agency (EMA) eligibility criteria for biologics were strictly applied, and phototherapy was included among first-line treatments. Methods: We followed a cohort of 1,090 patients who were referred to the only centre entitled to prescribe biologics and phototherapy during a 5-year period. Results: The cumulative number of treatment cycles was: 1,047 with NB-UVB phototherapy, 650 with systemic treatments and 239 with biologics; 754 patients received at least 1 course of NB-UVB phototherapy, 422 at least 1 course with a systemic treatment and 137 with a biologic; 595 patients were treated only with phototherapy. Conclusions: Regular use of NB-UVB as first-line treatment for moderate and severe psoriasis and adherence to the EMA eligibility criteria for biologics led to a relatively restricted use of biologics. (C) 2018 S. Karger AG, Basel

引用

页码：166 / 172

页数：7

共 18 条

[1] Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis [J].

Calzavara-Pinton, P. G. ;

Sala, R. ;

Arisi, M. ;

Rossi, M. T. ;

Venturini, M. ;

Ortel, B. .

BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 (01) :130-136

[2] Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis [J].

Davila-Seijo, P. ;

Dauden, E. ;

Carretero, G. ;

Ferrandiz, C. ;

Vanaclocha, F. ;

Gomez-Garcia, F. -J. ;

Herrera-Ceballos, E. ;

De la Cueva-Dobao, P. ;

Belinchon, I. ;

Sanchez-Carazo, J. -L. ;

Alsina, M. ;

Lopez-Estebaranz, J. -L. ;

Ferran, M. ;

Torrado, R. ;

Carrascosa, J. -M. ;

Llamas, M. ;

Rivera, R. ;

Jimenez-Puya, R. ;

Garcia-Doval, I. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (11) :1942-1950

[3]

Mitra S, DRG BLOG

[4]

O. S. Center Ohio supercomputer center, 1987, NON TRADITIONAL REF

[5]

Oji V, 2015, CLIN EXP RHEUMATOL, V33, pS14

[6] Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies [J].

Ormerod, A. D. ;

Augustin, M. ;

Baker, C. ;

Chosidow, O. ;

Cohen, A. D. ;

Dam, T. N. ;

Garcia-Doval, I. ;

Lecluse, L. L. ;

Schmitt-Egenolf, M. ;

Spuls, P. I. ;

Watson, K. D. ;

Naldi, L. .

DERMATOLOGY, 2012, 224 (03) :236-243

[7] European S3-Guidelines on the systemic treatment of psoriasis vulgaris [J].

Pathirana, D. ;

Ormerod, A. D. ;

Saiag, P. ;

Smith, C. ;

Spuls, P. I. ;

Nast, A. ;

Barker, J. ;

Bos, J. D. ;

Burmester, G-R ;

Chimenti, S. ;

Dubertret, L. ;

Eberlein, B. ;

Erdmann, R. ;

Ferguson, J. ;

Girolomoni, G. ;

Gisondi, P. ;

Giunta, A. ;

Griffiths, C. ;

Hoenigsmann, H. ;

Hussain, M. ;

Jobling, R. ;

Karvonen, S-L ;

Kemeny, L. ;

Kopp, I. ;

Leonardi, C. ;

Maccarone, M. ;

Menter, A. ;

Mrowietz, U. ;

Naldi, L. ;

Nijsten, T. ;

Ortonne, J-P ;

Orzechowski, H-D ;

Rantanen, T. ;

Reich, K. ;

Reytan, N. ;

Richards, H. ;

Thio, H. B. ;

van de Kerkhof, P. ;

Rzany, B. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 :1-70

[8]

Pearce-Smith N, 2011, NHS RIGHT CARE ESSEN

[9] BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE NAIVE PSORIATIC PATIENTS: A BUDGET IMPACT ANALYSIS IN ITALY [J].

Povero, M. ;

Pradelli, L. .

VALUE IN HEALTH, 2015, 18 (07) :A663-A664

[10] Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest [J].

Reich, K. ;

Mrowietz, U. ;

Radtke, M. A. ;

Thaci, D. ;

Rustenbach, S. J. ;

Spehr, C. ;

Augustin, M. .

ARCHIVES OF DERMATOLOGICAL RESEARCH, 2015, 307 (10) :875-883

← 1 2 →